(Total Views: 110)
Posted On: 05/05/2017 2:28:37 PM
Post# of 2218
$PETX Aratana Therapeutics (NASDAQ: PETX) which has had a “hiccup” or two after getting three drug approvals granted by the FDA in 2016. This unique veterinary drug play had to move back its launch of its compound Entyce from the first to the fourth quarter as it is switching manufacturing facilities and will need to go through a certification process with the FDA.
The company’s other approved drugs “Galliprant” and “Nocita” are just hitting the market, the latter through a marketing deal with Elanco. Aratana still has several compounds it is developing in its pipeline as well. Aratana has market capitalization of just $200 million, and approximately half of that is cash on the balance sheet. Given its cash hoard, recent approvals, and its pipeline, the stock’s recent 35% haircut seem entirely unwarranted. I have added some shares to my core stake recently on the pullback.
The company’s other approved drugs “Galliprant” and “Nocita” are just hitting the market, the latter through a marketing deal with Elanco. Aratana still has several compounds it is developing in its pipeline as well. Aratana has market capitalization of just $200 million, and approximately half of that is cash on the balance sheet. Given its cash hoard, recent approvals, and its pipeline, the stock’s recent 35% haircut seem entirely unwarranted. I have added some shares to my core stake recently on the pullback.
(0)
(0)Scroll down for more posts ▼
